Nango Daisuke, Hirose Yukifumi, Goto Makoto, Echizen Hirotoshi
Departments of Pharmacy, Shin-Yurigaoka General Hospital, 255 Furusawa-tsuko, Asao-ku, Kawasaki, Kanagawa 215-0026 Japan.
3Department of Pharmacotherapy, Meiji Pharmaceutical University, 2-522-1 Noshio, Kiyose, Tokyo, 204-8588 Japan.
J Pharm Health Care Sci. 2019 Feb 28;5:5. doi: 10.1186/s40780-019-0134-6. eCollection 2019.
There have been debates about the association between the administration of glucocorticoids and the development of acute pancreatitis, since many anecdotal cases of this adverse event were affected either by concomitant diseases (such as systemic lupus erythematosus, SLE) that may develop acute pancreatitis without glucocorticoid treatment or by co-administered drugs with high risk for the event. The aim of the present study was to explore whether disproportionally elevated signals of developing acute pancreatitis may be detected in patients receiving glucocorticoids as compared those receiving other drugs.
We retrieved spontaneously reported cases of acute pancreatitis and clinically related adverse events (target events) from the US Food and Drug Administration Adverse Event Reporting System (FAERS) using 18 preferred terms (PTs). Target drugs studied were cortisol, cortisone, prednisolone, methylprednisolone, triamcinolone, dexamethasone, and betamethasone. After cleaning the data, we calculated reporting odds ratios (RORs) and 95% confidence intervals (CIs) of acute pancreatitis in patients who received one of the glucocorticoids. RORs were calculated for each glucocorticoid using all reported cases irrespective of reporters' judgement about the contribution of the target drugs to events [i.e., primary suspected medication (PS), secondary suspected medication (SS), concomitant medication (C) and interacting (I)] and using cases with higher certainty of contribution (PS and SS), separately. When the lower limit of 95% CI of a ROR signal exceeded 1.0, the signal was considered statistically significant.
The RORs (95% CIs) calculated using all reported cases (PS, SS, C, and I) for cortisol (1.68; 1.43-1.98), prednisolone (1.33; 1.19-1.47), methylprednisolone (1.77; 1.55-2.02) were significant, whereas those for other target drugs were insignificant. Using the cases in which target drugs were considered to contribute the events with higher certainty (PS or SS), RORs for prednisolone (1.31; 1.10-1.55), methylprednisolone (1.62; 1.30-2.01), and dexamethasone (1.27; 1.10-1.47) were considered significant, whereas those for others were insignificant. Regarding the performance of PTs for detecting signals (RORs) associated with acute pancreatitis from FAERS database, "pancreatitis acute" gave RORs with higher significance than others, whereas more specific PTs, "haemorrhagic necrotic pancreatitis", "ischaemic pancreatitis", "pancreatic necrosis" and "pancreatitis necrotising", gave RORs with greater magnitude.
The present study demonstrated that the overrepresentation of signals for acute pancreatitis may be detected for prednisolone, methylprednisolone, and some others in the FAERS database.(372 words).
糖皮质激素的使用与急性胰腺炎的发生之间的关联一直存在争议,因为许多关于这一不良事件的轶事性病例要么受到可能在未使用糖皮质激素治疗的情况下发生急性胰腺炎的伴随疾病(如系统性红斑狼疮,SLE)影响,要么受到与该事件风险较高的联合用药影响。本研究的目的是探讨与接受其他药物治疗的患者相比,接受糖皮质激素治疗的患者是否会出现不成比例的急性胰腺炎发生风险升高信号。
我们使用18个首选术语(PTs)从美国食品药品监督管理局不良事件报告系统(FAERS)中检索了自发报告的急性胰腺炎及临床相关不良事件(目标事件)病例。所研究的目标药物为皮质醇、可的松、泼尼松龙、甲泼尼龙、曲安奈德、地塞米松和倍他米松。在清理数据后,我们计算了接受其中一种糖皮质激素治疗的患者发生急性胰腺炎的报告比值比(RORs)和95%置信区间(CIs)。分别使用所有报告病例(不考虑报告者对目标药物对事件的贡献判断,即主要怀疑用药(PS)、次要怀疑用药(SS)、伴随用药(C)和相互作用(I))以及贡献确定性较高的病例(PS和SS)计算每种糖皮质激素的RORs。当ROR信号的95%CI下限超过1.0时,该信号被认为具有统计学意义。
使用所有报告病例(PS、SS、C和I)计算的皮质醇(1.68;1.43 - 1.98)、泼尼松龙(1.33;1.19 - 1.47)、甲泼尼龙(1.77;1.55 - 2.02)的RORs(95% CIs)具有统计学意义,而其他目标药物的RORs无统计学意义。使用认为目标药物对事件贡献确定性较高的病例(PS或SS),泼尼松龙(1.31;1.10 - 1.55)、甲泼尼龙(1.62;1.30 - 2.01)和地塞米松(1.27;1.10 - 1.47)的RORs被认为具有统计学意义,而其他药物的RORs无统计学意义。关于从FAERS数据库中检测与急性胰腺炎相关信号(RORs)的PTs性能,“急性胰腺炎”给出的RORs比其他术语更具统计学意义,而更具体的PTs“出血坏死性胰腺炎”“缺血性胰腺炎”“胰腺坏死”和“坏死性胰腺炎”给出的RORs幅度更大。
本研究表明,在FAERS数据库中可检测到泼尼松龙、甲泼尼龙等药物的急性胰腺炎信号过度呈现。